581 related articles for article (PubMed ID: 22203527)
1. Metformin: multi-faceted protection against cancer.
Del Barco S; Vazquez-Martin A; Cufí S; Oliveras-Ferraros C; Bosch-Barrera J; Joven J; Martin-Castillo B; Menendez JA
Oncotarget; 2011 Dec; 2(12):896-917. PubMed ID: 22203527
[TBL] [Abstract][Full Text] [Related]
2. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer.
Menendez JA; Cufí S; Oliveras-Ferraros C; Martin-Castillo B; Joven J; Vellon L; Vazquez-Martin A
Aging (Albany NY); 2011 Nov; 3(11):1063-77. PubMed ID: 22170748
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer.
Jaromy M; Miller JD
Eur J Pharmacol; 2021 Apr; 897():173956. PubMed ID: 33617821
[TBL] [Abstract][Full Text] [Related]
4. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Joven J; Menendez JA
Cell Cycle; 2010 Nov; 9(22):4461-8. PubMed ID: 21088486
[TBL] [Abstract][Full Text] [Related]
5. Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Quirantes R; Segura-Carretero A; Micol V; Joven J; Bosch-Barrera J; Del Barco S; Martin-Castillo B; Vellon L; Menendez JA
Cell Cycle; 2012 Mar; 11(6):1235-46. PubMed ID: 22356767
[TBL] [Abstract][Full Text] [Related]
6. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions.
Vazquez-Martin A; López-Bonetc E; Cufí S; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
Drug Resist Updat; 2011; 14(4-5):212-23. PubMed ID: 21600837
[TBL] [Abstract][Full Text] [Related]
7. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
Cell Cycle; 2010 Sep; 9(18):3807-14. PubMed ID: 20890129
[TBL] [Abstract][Full Text] [Related]
8. Metformin: a rising star to fight the epithelial mesenchymal transition in oncology.
Barrière G; Tartary M; Rigaud M
Anticancer Agents Med Chem; 2013 Feb; 13(2):333-40. PubMed ID: 22721394
[TBL] [Abstract][Full Text] [Related]
9. Metformin is synthetically lethal with glucose withdrawal in cancer cells.
Menendez JA; Oliveras-Ferraros C; Cufí S; Corominas-Faja B; Joven J; Martin-Castillo B; Vazquez-Martin A
Cell Cycle; 2012 Aug; 11(15):2782-92. PubMed ID: 22809961
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
11. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development.
Gong J; Kelekar G; Shen J; Shen J; Kaur S; Mita M
Target Oncol; 2016 Aug; 11(4):447-67. PubMed ID: 26864078
[TBL] [Abstract][Full Text] [Related]
12. Metformin reverses stem cell‑like HepG2 sphere formation and resistance to sorafenib by attenuating epithelial‑mesenchymal transformation.
Feng Y; Guo X; Huang X; Wu M; Li X; Wu S; Luo X
Mol Med Rep; 2018 Oct; 18(4):3866-3872. PubMed ID: 30106125
[TBL] [Abstract][Full Text] [Related]
13. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.
Martin-Castillo B; Vazquez-Martin A; Oliveras-Ferraros C; Menendez JA
Cell Cycle; 2010 Mar; 9(6):1057-64. PubMed ID: 20305377
[TBL] [Abstract][Full Text] [Related]
14. Benefits of Metformin in Attenuating the Hallmarks of Aging.
Kulkarni AS; Gubbi S; Barzilai N
Cell Metab; 2020 Jul; 32(1):15-30. PubMed ID: 32333835
[TBL] [Abstract][Full Text] [Related]
15. Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells.
Soo JS; Ng CH; Tan SH; Malik RA; Teh YC; Tan BS; Ho GF; See MH; Taib NA; Yip CH; Chung FF; Hii LW; Teo SH; Leong CO
Apoptosis; 2015 Oct; 20(10):1373-87. PubMed ID: 26276035
[TBL] [Abstract][Full Text] [Related]
16. Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4.
Zhang J; Shen C; Wang L; Ma Q; Xia P; Qi M; Yang M; Han B
Biochem Biophys Res Commun; 2014 Sep; 452(3):746-52. PubMed ID: 25201727
[TBL] [Abstract][Full Text] [Related]
17. Multidimensional mechanisms of metformin in cancer treatment.
Singh-Makkar S; Pandav K; Hathaway D; Paul T; Youssef P
Tumori; 2022 Apr; 108(2):111-118. PubMed ID: 34139918
[TBL] [Abstract][Full Text] [Related]
18. Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells.
Saini N; Yang X
Acta Biochim Biophys Sin (Shanghai); 2018 Feb; 50(2):133-143. PubMed ID: 29342230
[TBL] [Abstract][Full Text] [Related]
19. Metformin's Modulatory Effects on miRNAs Function in Cancer Stem Cells-A Systematic Review.
Malinowski B; Musiała N; Wiciński M
Cells; 2020 Jun; 9(6):. PubMed ID: 32512882
[TBL] [Abstract][Full Text] [Related]
20. Repurposing old drugs to chemoprevention: the case of metformin.
Heckman-Stoddard BM; Gandini S; Puntoni M; Dunn BK; DeCensi A; Szabo E
Semin Oncol; 2016 Feb; 43(1):123-133. PubMed ID: 26970131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
